Safety issues of biologics in pregnant patients with rheumatic diseases

Annals of the New York Academy of Sciences

Volumn 1317, Issue 1, 2014, Pages 32-38

  Østensen, Monika ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Biological drugs; Glucocorticoids; Pregnancy; Rheumatic disease

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BELIMUMAB; BETAMETHASONE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; HYDROCORTISONE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADRENAL INSUFFICIENCY; ARTICLE; BRONCHIOLITIS; CHORIOAMNIONITIS; CLEFT PALATE; CONGENITAL MALFORMATION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; FETOTOXICITY; FIRST TRIMESTER PREGNANCY; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; INFECTION; INFECTION RISK; LOW BIRTH WEIGHT; MATERNAL BLOOD; NEUTROPENIA; NONHUMAN; OSTEOPENIA; PREGNANCY; PREGNANCY TERMINATION; PREGNANT WOMAN; PREMATURITY; PRENATAL DRUG EXPOSURE; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; THIRD TRIMESTER PREGNANCY; UMBILICAL CORD BLOOD; VASCULAR RESISTANCE; VASOCONSTRICTION;

BIOLOGICAL DRUGS; GLUCOCORTICOIDS; PREGNANCY; RHEUMATIC DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; FEMALE; GLUCOCORTICOIDS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RHEUMATIC DISEASES;

EID: 84901499266     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12456     Document Type: Article

References (57)

1. Jani, M. et al. 2013. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 53: 213-222.
2. Arida, A. et al. 2011. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin. Arthritis Rheum. 41: 61-70.
3. Famenini, S. & J.J. Wu 2013. Combination therapy with tumor necrosis factor inhibitors in psoriasis treatment. Cutis. 92: 140-147.
4. Murdaca, G., F. Spanò & F. Puppo 2013. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opin. Drug Saf. 12: 801-804.
5. Smolen, J.S. et al. 2014. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumaticdrugs: 2013 update. Ann Rheum. Dis. 73: 492-509.
6. Malek, A. et al. 1995. Transport of immunoglobulin G and its subclasses across the in vitro-perfused human placenta. Am. J. Obstet. Gynecol. 173: 760-767.
7. Suzuki, T. et al. 2010. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184: 1968-1976.
8. Mahadevan, U. et al. 2013. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 11: 286-292.
9. Nesbitt, T.A. et al. 2007. Effects of structure of conventional anti-TNFs and certolizumabpegol on mode of action in rheumatoid arthritis. Ann. Rheum. Dis. 66(Suppl 2): 296.
10. Murashima, A. et al. 2009. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann. Rheum. Dis. 68: 1793-1794.
11. Zelinkova, Z. et al. 2013. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin. Gastroenterol. Hepatol. 11: 318-321.
12. Cheent, K. et al. 2010. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J. Crohn. Colitis. 4: 603-605.
13. Berthelot, J.M. et al. 2009. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76: 28-34.
14. Schnitzler, F. et al. 2011. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm. Bowel Dis. 17: 1846-1854.
15. Nielsen, O.H., E.V. Jr Loftus & T. Jess 2013. Safety of TNF-αinhibitors during IBD pregnancy: a systematic review. BMC Med. 11: 174.
16. Diav-Citrin, O. et al. 2013. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: A prospective, comparative, observational study. Reprod. Toxicol. 43C: 78-84.
17. Carter, J.D. et al. 2009. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J. Rheumatol. 36: 635-641.
18. Crijns, H.J. et al. 2011. The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population. J. Rheumatol. 38: 1871-1874.
19. Clowse, M. et al. 2012. Outcomes of pregnancy in subjects exposed tocertolizumabpegol. Arthritis Rheum. 64(Suppl 10): S702.
20. Decker, M. et al. 2006. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 7: 693-694.
21. Friedrichs, B. et al. 2006. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91: 1426-1427.
22. Klink, D.T. et al. 2008. Rituximab administration in third trimester of pregnancy suppress neonatal B-cell development. Clin. Dev. Immunol. 2008: 271363.
23. Gall, B. et al. 2010. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J. Obstet. Gynaecol. Can. 32: 1167-1171.
24. Pendergraft, W.F. 3rd. et al. 2013. Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann. Rheum. Dis. 72: 2051-2053.
25. Sangle, S.R. et al. 2013. B-cell depletion therapy and pregnancy outcome in severe, refractory systemic autoimmune diseases. J. Autoimmun. 43: 55-59.
26. Chakravarty, E.F. et al. 2011. Pregnancy outcomes following maternal exposure to rituximab. Blood 117: 1499-506.
27. Vaidyanathan, A. et al. 2011. Developmental immunotoxicology assessment of rituximab in cynomolgusmonkeys. Toxicol. Sci. 119: 116-125.
28. Ton, E. et al. 2011. Safety of rituximab therapy during twins' pregnancy. Rheumatology (Oxford). 50:806-808.
29. Kapetanovic, MC. et al. 2014. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res. Ther. 16: R2.
30. Eisenberg, R.A. et al. 2013. Rituximab-treated patients have a poor response to influenza vaccination. J. Clin. Immunol. 33: 388-396.
31. Sagnelli, E. et al. 2012. Rituximab-based treatment, HCV replication, and hepatic flares. Clin. Dev. Immunol. 2012: 945950.
32. Pham, T. et al. 2009. Abatacept therapy and safety management. Joint Bone Spine 76(S1): S3-S55.
33. Kineret® Product Monograph. Regulatory Affairs Canada. August 8, 2008. http://www.kineret-eu.com/en/pro/faq/arifaq36.jsp.
34. Berger, C.T. et al. 2009. A patient's wish: anakinra in pregnancy. Ann. Rheum. Dis. 68: 1794-1795.
35. Fischer-Betz, R., C. Specker & M. Schneider 2011. Successful outcome of two pregnancies in patients with adult-onset Still's disease treated with IL-1 receptor antagonist (anakinra). Clin. Exp. Rheumatol. 29: 1021-1023.
36. Pham, T. et al. 2010. Tocilizumab: therapy and safety management. Joint Bone Spine 77(Suppl 1): S3-100.
37. Rubbert-Roth, A. et al. 2010. First experiences with pregnancies in RA patients receiving Tocilizumab therapy [abstract]. Arthritis Rheum. 62: S161.
38. Ishikawa, H. et al. 2012. Pregnancy in patients with rheumatoid arthritis treated with biological agents: results of the 8-year of Japanese TBC registry. Ann. Rheum. Dis. 71(Suppl3): 501.
39. Auyeung-Kim, D.J. et al. 2009. Developmental and peri-postnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reprod. Toxicol. 28: 443-455.
40. GlaxoSmithKline. 2013. Use of intravenous (IV) benlysta in pregnant patients with systemic lupus erythematosus (SLE).
41. Østensen, M. & F. Förger 2013. How safe are anti-rheumatic drugs in pregnancy? Curr. Op. Pharm. 13: 470-475.
42. Kaufmann, J. et al. 2013. Monotherapy with tocilizumab or TNF-alpha inhibitors in patients with rheumatoid arthritis: efficacy, treatment satisfaction, and persistence in routine clinical practice. Clin. Rheumatol. 32: 1347-1355.
43. Kajantie, E. et al. 2003. Placental 11 beta-hydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants. J. Clin. Endocrinol. Metab. 88: 493-500.
44. Khan, A.A. et al. 2011. Does in utero exposure to synthetic glucocorticoids influence birtahweight, head circumferenceand birth lenght: a systematic review of current evidence in humans. Pediatr. Perinat. Epidemiol. 25: 20-36.
45. Park-Wyllie, L. et al. 2000. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 6: 385-392.
46. Bay Bjørn, A.M. et al. 2014. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am. J. Ther. 21: 73-80.
47. Gur, C. et al. 2004. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod. Toxicol. 18: 93-101.
48. de Man, Y.A. et al. 2009. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 60: 3196-3206.
49. Nugent, J.L. et al. 2013. Chronic glucocorticoid exposure potentiates placental chorionic plate artery constriction: implications for aberrant fetoplacental vascular resistance in fetal growth restriction. Endocrinology 154: 876-887.
50. Kurtoglu, S. et al. 2011. Fetal adrenal suppression due to maternal corticosteroid use. J. Clin. Res. Pediatr. Endocrinol. 3: 160-162.
51. de Steenwinkel, F. et al. 2014. The influence of fetal prednisone exposure on the cortisol levels in the offspring. Clin. Endocrinol. (Oxf) 80: 804-810.
52. Deepak, P. Stobaugh, D.J. & Ehrenpreis, E.D. 2013. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J. Gastrointestin. Liver Dis. 22: 269-276.
53. Thamer, M. et al. 2009. Prednisone, lupus activity, and permanent organ damage. J. Rheumatol. 36: 560-564.
54. Danza, A. & G. Ruiz-Irastorza 2013. Infection risk in systemic lupus erythematosus patients: susceptibility factors and preventive strategies. Lupus 22: 1286-1294.
55. Migita, K. et al. 2013. Rates of serious intracellular infections in autoimmune disease patients receiving initial glucocorticoid therapy. PLoS One 8: e78699.
56. Strangfeld, A. et al. 2011. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann. Rheum. Dis. 70: 1914-1920.
57. Hyrich, K.L. & Verstappen, S.M. 2013. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) DOI: 10.1093/rheumatology/ket409.